{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:31:11Z","timestamp":1793615471833,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jiac.2026.103102","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:27:16Z","timestamp":1792510036000},"page":"103102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of isavuconazole prophylaxis for invasive fungal infections: A single-center retrospective study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9268-693X","authenticated-orcid":false,"given":"Yuto","family":"Kizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8831-1116","authenticated-orcid":false,"given":"Satoshi","family":"Yuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-2746","authenticated-orcid":false,"given":"Ikkou","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-9689","authenticated-orcid":false,"given":"Ryohkan","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103102_bib1","first-page":"75","article-title":"Rate, risk factors, and outcomes of invasive fungal infections in patients with hematologic malignancies","volume":"18","author":"Afhami","year":"2024","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.jiac.2026.103102_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cid\/ciae203","article-title":"Breakthrough invasive fungal infections in patients with high-risk hematological disorders receiving voriconazole and posaconazole prophylaxis: a systematic review","volume":"79","author":"Boutin","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s12879-025-11264-z","article-title":"Prevalence of invasive fungal infection in critically ill patients: a systematic review and meta-analysis","volume":"25","author":"Trelles","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2026.103102_bib5","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s40121-024-01064-4","article-title":"Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019)","volume":"13","author":"Neofytos","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2026.103102_bib6","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/jac\/dkae139","article-title":"Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study","volume":"79","author":"Erg\u00fcn","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.103102_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14162","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy and hematopoietic stem cell transplant patients","volume":"25","author":"Khatri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/ciy473","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Wingard","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection: position paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2026.103102_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jiac.2026.103102_bib12","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.103102_bib13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies: updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.jiac.2026.103102_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/jof9020166","article-title":"Comparing the real-world use of isavuconazole to other antifungal therapies for invasive fungal infections: a multicenter retrospective study","volume":"9","author":"Batista","year":"2023","journal-title":"J Fungi"},{"key":"10.1016\/j.jiac.2026.103102_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107070","article-title":"Safety and effectiveness of isavuconazole in real-life non-neutropenic patients: a multicentre observational study","volume":"144","author":"Monz\u00f3-Gallo","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A single-center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jiac.2026.103102_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the EORTC\/MSGERC","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib18","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","article-title":"EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the Intensive Care Unit Working Group","volume":"72","author":"Bassetti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciac623","article-title":"Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European Organization for Research and Treatment of Cancer","volume":"76","author":"Maertens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib20","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib21","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.4155\/fmc-2018-0252","article-title":"A survey of the role of nitrile groups in protein-ligand interactions","volume":"10","author":"Wang","year":"2018","journal-title":"Future Med Chem"},{"key":"10.1016\/j.jiac.2026.103102_bib22","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1039\/D1MD00131K","article-title":"Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies","volume":"12","author":"Wang","year":"2021","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.jiac.2026.103102_bib23","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.00319-09","article-title":"Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557","volume":"53","author":"Schmitt-Hoffmann","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103102_bib24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jiac.2026.103102_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jiac.2026.103102_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cpdd.281","article-title":"Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jiac.2026.103102_bib27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase II study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jiac.2026.103102_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103102_bib30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jiac.2026.103102_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2026.103102_bib32","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2019-131988","article-title":"Venetoclax dosing in combination with antifungal agents: real world experience in patients with acute myeloid leukemia","volume":"134","author":"Rausch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jiac.2026.103102_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12941-019-0311-3","article-title":"Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center","volume":"18","author":"Van","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiac.2026.103102_bib34","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients: a propensity score matched cohort analysis","volume":"59","author":"Bogler","year":"2021","journal-title":"Med Mycol"},{"key":"10.1016\/j.jiac.2026.103102_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myaf089","article-title":"Efficacy and safety of isavuconazole for invasive fungal infections: a systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Kawasaki","year":"2025","journal-title":"Med Mycol"},{"key":"10.1016\/j.jiac.2026.103102_bib36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/16078454.2022.2076046","article-title":"Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting","volume":"27","author":"Ping","year":"2022","journal-title":"Hematology"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2600200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2600200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:15:40Z","timestamp":1793614540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2600200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1341321X2600200X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103102","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of isavuconazole prophylaxis for invasive fungal infections: A single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103102"}}